In P. falciparum, plasmepsins I, II, IV and HAP have been directly implicated in hemoglobin degradation during malaria infection, and are now considered targets for anti-malarial drug design.
Metallo-β-lactamases (MBLs) play an important role in the emergence of microbial resistance to β-lactam antibiotics, and are hence considered targets for the design of novel therapeutics.
Many other chemokines have been considered targets for rheumatic diseases.
Combined efforts of this collaboration revealed potentially functional sequences within the LPHN3 gene that may be considered targets for future studies.
These results suggest BMLs and defects are interconnected and play key roles in knee cartilage volume loss; thus, both should be considered targets for intervention.
These results suggest BMLs and cartilage defects are interconnected and play key roles in knee cartilage volume loss; thus, both should be considered targets for intervention.
Therefore, they are currently not considered targets for antinociceptive therapy, although they might be involved in aspects of nociception [ 25, 31].
Multiple epigenetic factors are now considered targets for therapeutic strategies against cancer, and more studies are needed to elucidate the roles of epigenetic factors in tumor metastasis.
Then, CHC and cirrhosis should be considered targets for improving the survival of HIV-infected patients in the ICU in the future.
By contrast, none of the other 4 input target glycopeptides (which are incorrect candidates but still considered "targets", for the purposes of this demonstration), outscore the best decoy glycopeptide sequences generated by GPE.
